170 related articles for article (PubMed ID: 2987705)
1. The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.
Bussien JP; Nussberger J; Porchet M; Waeber B; Brunner HR; Perisic M; Tansey MJ; Bomm M; Hajdu P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Mar; 329(1):63-9. PubMed ID: 2987705
[TBL] [Abstract][Full Text] [Related]
2. A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man.
Manhem PJ; Ball SG; Morton JJ; Murray GD; Leckie BJ; Fraser R; Robertson JI
Br J Clin Pharmacol; 1985 Jul; 20(1):27-35. PubMed ID: 2992562
[TBL] [Abstract][Full Text] [Related]
3. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers.
Witte PU; Metzger H; Eckert HG; Irmisch R
Arzneimittelforschung; 1984; 34(10B):1448-51. PubMed ID: 6097272
[TBL] [Abstract][Full Text] [Related]
4. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
Böhm RO; van Baak MA; Rahn KH
Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic effects of a single 10-mg dose of the angiotensin converting enzyme inhibitor ramipril in patients with impaired renal function.
Ocón-Pujadas J; Debusmann ER; Jane F; Lahn W; Irmisch R; Mora J; Grötsch H
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S45-8. PubMed ID: 2474101
[TBL] [Abstract][Full Text] [Related]
6. CGS 13945: a new orally active angiotensin-converting enzyme inhibitor in normal volunteers.
Jacot des Combes B; Turini GA; Brunner HR; Porchet M; Chen DS; Sen S
J Cardiovasc Pharmacol; 1983; 5(4):511-6. PubMed ID: 6193344
[TBL] [Abstract][Full Text] [Related]
7. A potent converting enzyme inhibitor CGS 13928C. Drug profile in normal volunteers.
Schaller MD; Brunner DB; Nussberger J; Turini GA; Sen SB; Chen D; Waeber B; Brunner HR
Eur J Clin Pharmacol; 1984; 26(4):419-24. PubMed ID: 6329767
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
Karlberg BE; Lindström T; Rosenqvist U; Ohman KP
Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects.
Witte PU; Irmisch R; Hajdú P; Metzger H
Eur J Clin Pharmacol; 1984; 27(5):577-81. PubMed ID: 6097458
[TBL] [Abstract][Full Text] [Related]
10. Unchanged pressor effect of norepinephrine in normal man following the oral administration of two angiotensin converting enzyme inhibitors, captopril and HOE 498.
Vierhapper H; Witte PU; Waldhäusl W
J Hypertens; 1986 Feb; 4(1):9-11. PubMed ID: 3007605
[TBL] [Abstract][Full Text] [Related]
11. Twenty-four hour changes in active and inactive renin after various oral doses of the converting enzyme inhibitor ramipril (HOE498) in normal man.
Malatino LS; Manhem P; Ball SG; Leckie BJ; Morton JJ; Murray GD; Robertson JI
J Clin Hypertens; 1986 Sep; 2(3):231-7. PubMed ID: 3023553
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients.
Gilchrist WJ; Beard K; Manhem P; Thomas EM; Robertson JI; Ball SG
Am J Cardiol; 1987 Apr; 59(10):28D-32D. PubMed ID: 3034029
[TBL] [Abstract][Full Text] [Related]
13. Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme.
Düsing R; Kayser G; Wagner S; Scherf H; Glänzer K; Predel HG; Kramer HJ
Am J Cardiol; 1987 Apr; 59(10):50D-54D. PubMed ID: 3034033
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Becker RH; Schölkens BA; Metzger M; Schulze KJ
Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Schölkens BA; Becker RH; Kaiser J
Arzneimittelforschung; 1984; 34(10B):1417-25. PubMed ID: 6097268
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man.
MacDonald NJ; Hughes DM; Lees KR; Reid JL
Br J Clin Pharmacol; 1990 Jul; 30(1):107-13. PubMed ID: 2202384
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288.
Gohlke P; Schölkens B; Henning R; Urbach H; Unger T
J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S32-6. PubMed ID: 2483426
[TBL] [Abstract][Full Text] [Related]
18. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.
Brunner DB; Desponds G; Biollaz J; Keller I; Ferber F; Gavras H; Brunner HR; Schelling JL
Br J Clin Pharmacol; 1981 May; 11(5):461-7. PubMed ID: 6268131
[TBL] [Abstract][Full Text] [Related]
19. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.
Unger T; Ganten D; Lang RE; Schölkens BA
J Cardiovasc Pharmacol; 1984; 6(5):872-80. PubMed ID: 6209494
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important.
Wenting GJ; Blankestijn PJ; Poldermans D; van Geelen J; Derkx FH; Man in't Veld AJ; Schalekamp MA
Am J Cardiol; 1987 Apr; 59(10):92D-97D. PubMed ID: 3034041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
